Strategies for treating cancers caused by multiple genome abnormalities: From concepts to cures?

Current Opinion in Investigational Drugs

Volumn 4, Issue 12, 2003, Pages 1410-1415

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRAF gene; Genome targets; Hsp90; Oncogenes

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 17 DESMETHOXY 17 N,N METHYLAMINOETHYLAMINOGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYTOTOXIC AGENT; ERLOTINIB; FR 901228; GEFITINIB; GELDANAMYCIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PYROXAMIDE; ROSCOVITINE; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER; CHRONIC MYELOID LEUKEMIA; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; ONCOGENE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; GENOMICS; HUMANS; NEOPLASMS;

EID: 1642475106     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Workman P: Scoring a bull's-eye against cancer genome targets. Curr Opin Pharmacol (2001) 1(4):342-352.
2. Workman P: The impact of genomic and proteomic technologies on the development of new cancer drugs. Ann Oncol (2002) 13(Suppl 4):115-124.
3. Debouck C, Goodfellow PN: DNA microarrays in drug discovery and development. Nat Genet (1999) 21(1 Suppl):48-50.
4. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419(6907):624-629. An excellent example of a new potential target discovered by gene expression microarray analysis and validated by gene transfection and RNAi technology. In this case, the histone methyltransferase EZH2, a chromatin-modifying enzyme, was identified as an important gene product in metastatic prostate cancer.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins C, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-954. The first molecular drug target to emerge from the UK-based Cancer Genome Project. High-throughput genome sequencing of large numbers of cancer cell lines and tissues identified BRAF as a gene that is frequently mutated in human cancer, especially melanoma.
6. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JKV, Parmigiani G, Kinzler KW, Volgelstein B et al.: Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 300(5621):949. High-throughput sequencing of the tyrosine kinome in colorectal cancers identified several additional mutated kinases that may be potential drug targets.
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of the 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
8. Workman P, Kaye SB: Translating basic cancer research into new cancer therapeutics. Trends Mol Med (2002) 8(4 Suppl):S1-S9.
9. Lee JT, McCubrey JA: BAY-43-9006 (Bayer/Onyx). Curr Opin Invest Drugs 4(6):757-763.
10. Ratain JJ, O'Dwyer P, Stadler W, Kaye SB, Xiong H, Eisen T, Patnaik A, Smith M, Flaherty KT, Kindler H, Lee RJ et al.: A phase II study of BAY 43-9006 using the randomised discontinuation design in patients with advanced refractory cancer. Proc Int Symp Signal Transduction Modulators Cancer Ther (2003) 2:Abs O.24
11. Druker BJ: STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med (2002) 8(4 Suppl):S14-S18.
12. Balmain A, Gray J, Ponder B: The genetics and genomics of cancer. Nat Genet (2003) 33(Suppl):S238-S244. Excellent overview of the current status and thinking about the genetics and genomics of human cancer, with major implications for drug development strategies.
13. Kinzler KW, Vogelstein B: Colorectal tumors. In: The Genetic Basis of Human Cancer. Vogelstein B, Kinzler KW (Eds), McGraw Hill, London, UK (2002):583-612.
14. De Bono JS, Rowinsky EK: The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med (2002) 8(4 Suppl):S19-S26.
15. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 297(5578):102-104. An example of an experimental animal model in which knocking out a single gene, even if only briefly, can lead to a persistent reversal of the malignant phenotype. The relevance of such models to such multigenic human malignancy is not clear, but such models can be valuable for understanding the development of cancer and the design of molecular therapeutic strategies.
16. Workman P: Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther (2002) 2(6):611-614.
17. Workman P: The opportunities and challenges of personalized genome-based molecular therapies for cancer: Targets, technologies and molecular chaperones. Cancer Chemother Pharmacol (2003) 52(Suppl 1):S45-S56. A recent detailed review of the progress and potential of molecular therapeutic strategies for cancer and in particular the challenges of tackling multiple gene targets. The development of inhibitors of the Hsp90 molecular chaperone is used as an example of how to attack multigene cancer with a single specific agent.
18. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 63(14):3883-3885.
19. Weinstein IB: Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science (2002) 297(5578):63-64. An influential early commentary dealing with the concept of oncogene addiction. This concept has influenced thinking about the selectivity of drugs for cancer versus normal cells, although rigorous experimental validation of the concept has required, particularly with respect to the mechanism of action of molecular therapeutics.
20. She QB, Solit D, Basso A, Moasser MM: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res (2003) 9(12):4340-4346.
21. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 2(7):489-501.
22. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P: Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol (2003) 10(3):207-213. Timely review of the emerging potential of PI3 kinase inhibitors in cancer and other diseases.
23. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbuch S, Fandi A: A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT I). Ann Oncol (2002) 13(Suppl 5):2.
24. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S, Grous J: ZD1839 (Iressa) in combination with paclixatel and carboplatin in chemotherapy naïve patients with advanced non-small cell lung cancer (NSCLC): Results from a phase III trial (INTACT 2). Ann Oncol (2002) 13(Suppl 5):127.
25. Natale RB: Gefitinib (Iressa): The first effective EGFR-targeted agent in non-small cell lung cancer. Proc Int Symp Signal Transduction Modulators Cancer Ther (2003) 2:Abs O.21.
26. Whittaker SR, Walton MI, Garrett M, Workman P: The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits RB phosphorylation, causes loss of cyclin D1 and activates the mitogen-activated protein kinase pathway. Cancer Res (2003):in press.
27. Adams J: Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med (2002) 8(4 Suppl):S49-S54.
28. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer (2001) 1(3):194-202.
29. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 2(2):151-163.
30. Kelly WK, Richon VM, O'Connor O, Curley Y, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M et al.: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 9(10 Pt 1):3578-3588. First full publication dealing with the phase I clinical trial of the histone deacetylase inhibitor SAHA.
31. Brown R, Strathdee G: Epigenomics and epigenetic therapy of cancer. Trends Mol Med (2002) 8(4 Suppl):S43-S48.
32. Kouzarides T: Acetylation: A regulatory modification to rival phosphorylation? EMBO J (2000) 19(6):1176-1179.
33. Strahl BD, Allis CD: The language of covalent histone modifications. Nature (2000) 403(6765):41-45.
34. Maloney A, Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther (2002) 2(1):3-24. A detailed review of the Hsp90 molecular chaperone and its important potential as a drug target.
35. Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3(3):213-217. An update on the therapeutic potential of Hsp90 inhibitors focusing on the various cancer types in which particular molecular chaperone client proteins may play key roles.
36. Sausville EA, Tomaszewski JE, Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets (2003) 3(5):377-383. Along with reference, this is a valuable and up-to-date summary of the ongoing clinical development of the first-in-class inhibitor of Hsp90, 17-AAG.
37. Banerji U, Judson I, Workman P: The clinical applications of heat shock protein inhibitors in cancer - Present and future. Curr Cancer Drug Targets (2003) 3(5):385-390. A review that complements reference, focusing on how Hsp90 inhibitors might be used in the clinic, and the prospects for novel inhibitors of the molecular chaperone.
38. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high affinity conformation of Hsp90 confers tumor selectivity in Hsp90 inhibitors. Nature (2003) 425(6956):407-410. A fascinating paper which shows that the therapeutic index of 17-AAG may relate to a major difference in the molecular state of the Hsp90 between cancer and normal cells. The molecular chaperone is present in an uncomplexed form in normal cells, whereas in cancer cells, Hsp90 is found in a multichaperone complex that is more active as an ATPase-driven chaperone, and also more sensitive to inhibition by 17-AAG.
39. Rutherford SL, Lindquist S: Hsp90 as a capacitor for morphological evolution. Nature (1998) 396(6709):336-342.
40. Choisis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets (2003) 3(5):371-376.
41. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.